Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
25 search results for:

Follicular lymphoma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 19-10-2018 | Follicular lymphoma | News | Article

    Post-induction PET predicts outcome in follicular lymphoma

    Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.

    Published in:
    Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30618-1
  2. 06-09-2018 | Follicular lymphoma | News | Article

    Lenalidomide plus rituximab comparable to follicular lymphoma standard of care

    Treatment-naïve follicular lymphoma patients have similar outcomes regardless of whether they receive lenalidomide or chemotherapy in combination with rituximab, suggest phase III trial findings published in The New England Journal of Medicine .

    Published in:
    N Engl J Med 2018; 379 : 934–947
  3. 06-10-2017 | Follicular lymphoma | News | Article
    Editor's pick

    Obinutuzumab may improve follicular lymphoma outcome

    Treatment with obinutuzumab-based chemotherapy prolongs progression-free survival over rituximab-based therapy in patients with follicular lymphoma, GALLIUM trial data suggest.

    Published in:
    N Engl J Med 2017; 377 : 1331–1344, 1389–1390
  4. 25-08-2017 | Lymphoma | Article

    Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma

    ​​​​​​​ Blood Cancer J 2017; 7: e595. doi:10.1038/bcj.2017.70

    Author:
    SI Tracy, MJ Maurer, TE Witzig, MT Drake, SM Ansell, GS Nowakowski, CA Thompson, DJ Inwards, PB Johnston, IN Micallef, C Allmer, WR Macon, GJ Weiner, SL Slager, TM Habermann, BK Link, JR Cerhan
  5. 20-02-2018 | Follicular lymphoma | Article

    A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts

    Huet S et al. N Eng J Med 2018; 19(4): 549-561. doi:10.1016/S1470-2045(18)30102-5

  6. 03-12-2020 | COVID-19 | News | Article

    Clinical guidance may impact cancer treatment rates during COVID-19

    However, the number of registrations for neoadjuvant therapies, chronic lymphocytic leukemia, and follicular lymphoma and Waldenström macroglobulinemia remained significantly lower in June 2020 compared with the control period.

    Author:
    Laura Cowen
    Published in:
    Lancet Oncol 2020; doi:10.1016/S1470-2045(20)30619-7
  7. 19-05-2017 | Breast cancer | News | Article

    In other news

    Here we report on osteoporosis therapy in breast cancer patients, the feasibility of an alternative formulation of rituximab in follicular lymphoma, the effects of extended use of anamorelin on lung cancer-related cachexia, and the 3-year results of the COMBI-d trial.

  8. 23-03-2017 | Lymphoma | News | Article

    Excessive toxicity halts idelalisib, lenalidomide plus rituximab lymphoma trials

    Two phase 1 trials investigating the safety and efficacy of combined idelalisib, lenalidomide, and rituximab in patients with relapsed and refractory follicular and mantle cell lymphoma have been stopped early due to excessive toxicity.

    Published in:
    Lancet Haematol 2017; Advance online publication
  9. 22-12-2017 | B-cell lymphoma | News | Article

    CAR T-cell therapy effective for refractory large B-cell lymphomas

    The first of these – a multicenter phase II trial that was reported simultaneously at the 2017 American Society of Hematology Annual Meeting in Atlanta, Georgia, USA – enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma that had not responded to prior treatment.

    Published in:
    N Engl J Med 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA
  10. 15-05-2018 | FDA | News | Article
    approvalsWatch

    Tisagenlecleucel approved for relapsed, refractory DLBCL

    The CD-19-directed genetically modified autologous T-cell immunotherapy may be used for patients with forms of the disease including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  11. 23-11-2017 | FDA | News | Article
    approvalsWatch

    FDA announces approvals for sunitinib, obinutuzumab

    By Shreeya Nanda medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group See also: Obinutuzumab may improve follicular lymphoma outcome

  12. 19-10-2017 | CAR T-cell immunotherapy | News | Article
    approvalsWatch

    Second CAR T-cell therapy receives FDA approval

    Read more on this decision affecting treatment of some types of large B-cell lymphoma here

  13. 20-09-2017 | FDA | News | Article
    approvalsWatch

    Copanlisib, low-dose cabazitaxel receive FDA go ahead

    Copanlisib, a class I phosphoinositide 3-kinase inhibitor, may now be used by adults who have previously received at least two prior systemic treatments for follicular lymphoma, including rituximab and an alkylating agent.

  14. 07-07-2017 | FDA | News | Article
    approvalsWatch

    Rituximab–hyaluronidase human combination approved for multiple indications

    medwireNews : The FDA has granted regular approval for combined use of subcutaneous rituximab and hyaluronidase human for follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL).

  15. 31-08-2017 | Lymphoma | Article

    Chimeric antigen receptor T-cell therapies for lymphoma

    ​​​​​​​ Nat Rev Clin Oncol  2017. doi:10.1038/nrclinonc.2017.128

    Author:
    Jennifer N. Brudno, James N. Kochenderfer
  16. 21-04-2017 | Lymphoma | Feature | Article

    Lymphoma in practice: Professor Anas Younes speaks to medwireNews

    Professor Anas Younes tells  medwireNews about the current issues in lymphoma practice, both for the clinician and patients.

  17. 04-05-2017 | Diffuse large B-cell lymphoma | News | Article

    Lenalidomide maintenance delays disease progression in DLBCL

    Lenalidomide maintenance therapy significantly improves progression-free survival in elderly patients with diffuse large B-cell lymphoma who respond to first-line chemotherapy, phase III trial data show.

    Published in:
    J Clin Oncol 2017; Advance online publication
  18. 01-08-2016 | Lymphoma | Article

    Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine

    An expert summary of the diagnostic and prognostic value of biomarkers related to alterations in the most common types of lymphoma at the genetic, epigenetic, protein, and tumor microenvironment levels. Mod Pathol  2016; 29: 1118–1142. doi:10.1038/modpathol.2016.92

    Author:
    Ruifang Sun, L Jeffrey Medeiros, Ken H Young
  19. 14-03-2017 | Lymphoma | Case report | Article

    SLL and CLL

    Work up and diagnosis At the time of diagnosis, it is important to confirm that the patient has CLL/SLL and not a masquerading lymphoproliferative disorder like hairy cell leukemia or the leukemic phase of mantle cell lymphoma, marginal zone lymphoma, or follicular lymphoma.

    Author:
    Tanya Siddiqi, Steven T Rosen
  20. 24-02-2017 | Liquid biopsy | Review | Article

    Liquid biopsies come of age: Towards implementation of circulating tumor DNA

    This revealed an increased contribution of cfDNA from B lymphocytes, which was consistent with a diagnosis of follicular lymphoma 67 .

    Author:
    Jonathan C. M. Wan, Charles Massie, Javier Garcia-Corbacho, Florent Mouliere, James D. Brenton, Carlos Caldas, Simon Pacey, Richard Baird, Nitzan Rosenfeld

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.